<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04810962</url>
  </required_header>
  <id_info>
    <org_study_id>CPN-302</org_study_id>
    <nct_id>NCT04810962</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study</brief_title>
  <official_title>A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of APP13007 for the Treatment of Inflammation and Pain After Cataract Surgery, Including a Corneal Endothelial Cell Sub-study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Formosa Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Formosa Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3 study will evaluate APP13007 in comparison to the matching vehicle placebo in a&#xD;
      randomized, parallel-group, double-masked fashion. The subjects will have undergone routine&#xD;
      cataract surgery on Day 0 of the study and will be assessed the next day (Post-operative Day;&#xD;
      POD1) after uncomplicated surgery for eligibility for randomization to study treatment. The&#xD;
      study comprises the Main Study and the Endothelial Cell Sub-study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy as Assessed by Anterior Chamber Cell (ACC) Count</measure>
    <time_frame>Postoperative Day 8 through Postoperative Day 15</time_frame>
    <description>Proportion of subjects with ACC count = 0 (0 = 0 ACC, 2 = 1-5 ACC, 3 = 6-15 ACC, 4 = 16-30 ACC, 5 = &gt;30 ACC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy as Assessed by Ocular Pain Grade</measure>
    <time_frame>Postoperative Day 4 through Postoperative Day 15</time_frame>
    <description>Proportion of subjects with Ocular Pain Grade = 0 (0 = no pain; 4 = severe pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as Assessed by Adverse Events (AEs)</measure>
    <time_frame>Screening through Postoperative Day 22</time_frame>
    <description>Incidence of ocular and systemic AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as Assessed by Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>Screening through Postoperative Day 22</time_frame>
    <description>The visual acuity in each eye is corrected using the pinhole method and the acuity is quantified on a logMAR (minimal angle of resolution) scale using the 'Early Treatment Diabetic Retinopathy Study' [ETDRS] charts for right and left eyes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as Assessed by Ocular Anatomy</measure>
    <time_frame>Screening through Postoperative Day 22</time_frame>
    <description>Ocular anatomy is routinely assessed using slit-lamp biomicroscopy and dilated indirect ophthalmoscopy. Ocular tissues are examined at each study visit and any anatomical abnormalities are recorded using standard medical descriptive terminology.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as Assessed by Corneal Endothelial Cell Measurements</measure>
    <time_frame>Screening through Postoperative Day 85</time_frame>
    <description>Mean changes in corneal endothelial cell density (units: cells/mm2), percent hexagonality (units: % of cells with hexagonal shape) and coefficient of variation in the sizes of the endothelial cells (units: % variation in size between endothelial cells) will be measured from the images obtained using a specular microscope.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as Assessed by Intraocular Pressure (IOP)</measure>
    <time_frame>Screening through Postoperative Day 22</time_frame>
    <description>Change from baseline in IOP using the Goldman applanation tonometer to each visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy as Assessed by Anterior Chamber Cell (ACC) Count</measure>
    <time_frame>Through Postoperative Day15</time_frame>
    <description>Proportion of subjects with ACC count = 0 (0 = 0 ACC, 2 = 1-5 ACC, 3 = 6-15 ACC, 4 = 16-30 ACC, 5 = &gt;30 ACC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as Assessed by Ocular Pain Grade</measure>
    <time_frame>Through Postoperative Day 15</time_frame>
    <description>Proportion of subjects with Ocular Pain Grade = 0 (0 = no pain; 4 = severe pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as Assessed by Anterior Chamber Flare (ACF)</measure>
    <time_frame>Through Postoperative Day 15</time_frame>
    <description>Proportion of subjects with ACF Grade = 0 (0 = none; 4 = intense)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as Assessed by Anterior Chamber Flare (ACF)</measure>
    <time_frame>Postoperative Day 8 through Postoperative Day 15</time_frame>
    <description>Proportion of subjects with ACF Grade = 0 (0 = none; 4 = intense)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as Assessed by Anterior Chamber Cell Count (ACC)</measure>
    <time_frame>Through Postoperative Day 15</time_frame>
    <description>Mean change in baseline in ACC Grade. Measurement of ACC grade using a slit lamp biomicroscope and a 5 point grading scale (0 = 0 ACC, 2 = 1-5 ACC, 3 = 6-15 ACC, 4 = 16-30 ACC, 5 = &gt;30 ACC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as Assessed by Ocular Pain Grade</measure>
    <time_frame>Through Postoperative Day 15</time_frame>
    <description>Mean change in baseline in Ocular Pain Grade. Measurement of Ocular Pain Grade using a slit lamp biomicroscope and a 5 point grading scale (0 = no pain; 4 = severe pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as Assessed by Anterior Chamber Flare (ACF)</measure>
    <time_frame>Through Postoperative Day 15</time_frame>
    <description>Mean change in baseline in ACF Grade. Measurement of ACF using a slit lamp biomicroscope and a 5 point rating scale (0 = none; 4 = intense)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as Assessed by Number of Subjects Rescued</measure>
    <time_frame>Postoperative Day 1 through Postoperative Day 22</time_frame>
    <description>Number of subjects rescued on or prior to each visit and overall</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Ocular Inflammation and Pain After Cataract Surgery</condition>
  <arm_group>
    <arm_group_label>APP13007 0.05% BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop APP13007 0.05% twice daily for 14 days to study (operated) eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Vehicle Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 drop matching vehicle placebo twice daily for 14 days to study (operated) eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APP13007, 0.05%</intervention_name>
    <description>APP13007 eye drop, 0.05%</description>
    <arm_group_label>APP13007 0.05% BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Vehicle Placebo for APP13007, 0.05%</intervention_name>
    <description>Matching vehicle placebo eye drop</description>
    <arm_group_label>Matching Vehicle Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 years of age or older expected to undergo unilateral uncomplicated&#xD;
             cataract extraction via phacoemulsification and posterior chamber intraocular lens&#xD;
             implantation in one eye.&#xD;
&#xD;
          -  Have a pin-hole corrected visual acuity without other correction of â‰¤ 1.3 logarithm of&#xD;
             the minimum angle of resolution (logMAR) in the study eye to be operated and&#xD;
             contralateral eye as measured using an Early Treatment Diabetic Retinopathy Study&#xD;
             (ETDRS) chart at Visit 1.&#xD;
&#xD;
          -  Willing and able to comply with study requirements and visit schedule.&#xD;
&#xD;
          -  Provide signed and dated informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a known sensitivity or allergy to clobetasol propionate, corticosteroids, or any&#xD;
             of the study medication's components including benzalkonium chloride and soybean&#xD;
             lecithin or any routine medication required during cataract surgery or for the conduct&#xD;
             of study procedures&#xD;
&#xD;
          -  Have an ACC count &gt; 0 or any evidence of intraocular inflammation (e.g., flare) in&#xD;
             either eye at the Screening visit&#xD;
&#xD;
          -  Have a Grade &gt; 0 on the Ocular Pain Assessment in either eye at the Screening visit&#xD;
&#xD;
        Note: Other inclusion/exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Ops Representative</last_name>
    <phone>919-797-1146</phone>
    <email>clin.ops@aimmaxrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Carrot Eye Center</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cornea and Cataract Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orange County Ophthalmology Medical Group</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92843</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Premiere Practice Management, LLC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visionary Research Institute</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Bay Eye Associates</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sierra Clinical Trials Research Organization</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wolstan and Goldberg Eye Associates</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michael K. Tran, MD, Inc.</name>
      <address>
        <city>Westminster</city>
        <state>California</state>
        <zip>92683</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rand Eye Institute</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eye Associates for Fort Myers</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Levenson Eye Associates</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>International Research Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dixon Eye Care</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <zip>31701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clayton Eye Clinical Research LLC</name>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chicago Cornea Consultants</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stiles Eyecare Excellence and Glaucoma Institute, PA</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Eye Care Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fraser Eye Center</name>
      <address>
        <city>Fraser</city>
        <state>Michigan</state>
        <zip>48026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tauber Eye Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Associates</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wellish Vision Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Metropolitan Eye Research and Surgery Institute</name>
      <address>
        <city>Palisades Park</city>
        <state>New Jersey</state>
        <zip>07650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alterman, Modi and Wolter</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eye Care Specialists</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina Cataract and Laser Center</name>
      <address>
        <city>Ladson</city>
        <state>South Carolina</state>
        <zip>29456</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Black Hills Regional Eye Institute</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Eye Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Round Rock Eye Consultants</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Capsule Opacification</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

